Restoration of Spectral Resolution With Hearing-aid Amplification

Hearing Loss Clinical Trial

Official title:

Restoration of Spectral Resolution With Hearing-aid Amplification

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03850678
• Other study ID #: 18892
• Secondary ID: R21DC017588
• Status: Completed
• Phase: N/A
• Start date: April 2, 2019
• Est. completion date: November 30, 2023

Study information

• Verified date: February 2024
• Source: University of Nebraska Lincoln
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study protocol is to determine the efficacy of using aided measures of spectral resolution to set the dynamic range of hearing with hearing-aid amplification. Measures of spectral resolution will be obtained, as will measures of speech recognition.

Description:

Adults with hearing loss are more vulnerable to interference from background noise than adults with normal hearing. Despite the fact that the ability to extract speech information imbedded in background noise requires decoding differences in level across frequency (spectral information), few studies have addressed the extent to which spectral information can be provided to listeners with hearing loss. This fundamental gap in our knowledge prevents society from effectively addressing the systemic effects of hearing loss on communication, income, and ability to socialize with others. This work is a new application of established methods of characterizing spectral resolution to that of the most common device for rehabilitation of hearing loss, hearing-aid amplification. Because hearing aids do not require premarket approval, FDA oversight is not applicable to this clinical trial.

The experiments will examine the degree to which access to spectral information can be restored to adults with hearing loss and the feasibility of utilizing this information to decrease interference from background noise. Aim 1 will delineate the impact of hearing-aid amplification on spectral decoding. Technology options that must be set by the clinician or hearing-aid manufacturer will be examined, including the frequency-specific gain, compressor speed, and number of compression channels. The proposed experiments will test the hypothesis that restoration of the lost dynamic range of hearing can support the encoding of spectral information. It is also hypothesized that the combination of technology options that best restore access to spectral information will differ across individuals and that these differences across individuals can be partially accounted for by an estimate of outer hair cell function. Aim 2 will determine the extent to which restoring access to spectral information supports speech recognition in background noise, under the guiding hypothesis that improving spectral resolution increases speech understanding. If it can be demonstrated that measures of spectral resolution with the provision of amplification are useful at delineating those who stand to benefit from different technology options, the knowledge gained could then be applied to the clinic to allow for clinicians to more successfully choose among different rehabilitation options.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• normal tympanograms (peak admittance of = 0.2 mmhos, -200 to 50); Hearing thresholds for normal hearing group less than or equal to 20 decibels in hearing level (dB HL) from .25 to 8 kHz. Pure-tone average (2, 4 & 6 kHz) hearing thresholds for participants with hearing loss of 30 - 65 dB HL.

Exclusion Criteria:

• cognitive impairment

Related Conditions & MeSH terms

• Hearing Loss

Intervention

Device:
• Hearing Aid
Hearing Aid

Locations

Country	Name	City	State
United States	Barkley Memorial Center	Lincoln	Nebraska

Sponsors (2)

Lead Sponsor	Collaborator
University of Nebraska Lincoln	National Institute on Deafness and Other Communication Disorders (NIDCD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Spectral resolution	Measure of spectral resolution (Q10) obtained from the fast psychophysical tuning curve test	Each test is approximately 10 minutes and will be completed after each experimental manipulation
Primary	Speech Recognition	measure of percent correctly repeated words embedded in sentences and background noise	Each test is approximately 10 minutes and will be completed after each experimental manipulation
Secondary	Working memory	Measure of working memory (correctly repeated words and sentences from the reading span test)	Each test is approximately 30 minutes and will be completed once per subject